Friess Associates’s Biogen BIIB Stock Holding History

Friess Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,200	Closed	-$3.07M	–	109
2018 Q1	$3.07M	Buy	+11,200	New	+$3.48M	0.25%	83

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Friess Associates's BIIB Position: Q2 2018 in Review

Friess Associates sold out of Biogen (BIIB) in Q2 2018, closing a stake of 11,200 shares — an estimated $3.07M sold.

Friess Associates first reported a position in BIIB in Q1 2018 and held it in 1 quarter. The position peaked at $3.07M in Q1 2018. 1,097 funds tracked by Wall St. Rank hold BIIB as of Q2 2018.

Friess Associates reported no remaining Biogen position as of Q2 2018 after selling out during the quarter.
Friess Associates sold 11,200 Biogen shares in Q2 2018, an estimated $3.07M.
Friess Associates first reported a position in Biogen in Q1 2018 and held it in 1 quarter.
Friess Associates's Biogen position peaked at $3.07M in Q1 2018.
1,097 funds tracked by Wall St. Rank held Biogen as of Q2 2018.

Based on Friess Associates's 13F filing for Q2 2018, filed 14 Aug 2018.